Clearview Cancer Center

Quick Links:

Clearview News Wire

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.



FDA approves BTG's drug for cancer toxicity

January 18, 2012

Last Updated: 2012-01-18 10:15:27 -0400 (Reuters Health)

WASHINGTON (Reuters) - U.S. health regulators gave the nod on Tuesday to a drug from British specialty drugmaker BTG Plc that helps cancer patients get rid of toxic levels of a chemotherapy treatment.

The drug, called Voraxaze, helps eliminate methotrexate in patients whose kidney function has been compromised by treatment with high doses of the chemotherapy agent. Methotrexate is normally eliminated from the body by the kidneys, but prolonged high doses of the drug used to treat cancer can result in kidney failure.

BTG's injectable treatment can quickly break down the chemotherapy medicine and allow the body to expel it.

The Food and Drug Administration granted Voraxaze orphan drug status, meant for rare diseases or conditions that affect a very small portion of the population. As incentive for companies to develop such drugs, the orphan designation comes with seven years of marketing exclusivity before a rival medicine could be approved.

Methotrexate is used to treat breast, bone and lung cancer as well as leukemia. In much lower doses, it is commonly used to treat rheumatoid arthritis and other autoimmune diseases.

Prolonged exposure to the chemotherapy treatment can cause kidney and liver damage, skin rash and severe mouth sores, damage to the lining of the intestines, and death because of low blood cell counts, said Richard Pazdur, the head of the FDA's cancer drugs division.

"Voraxaze is an important new treatment option for cancer patients aimed at preventing these toxicities associated with sustained high levels of methotrexate," Pazdur said in a statement.

In a clinical trial of 22 patients, Voraxaze eliminated 95 percent of methotrexate from their blood. For 10 of the patients, the methotrexate fell to a low level within 15 minutes and stayed that way for eight days, the FDA said.

Common side effects included low blood pressure, headaches, nausea and vomiting.

Other Articles:

February 16, 2012
In prostate cancer, other death risks may be higher
February 14, 2012
Vitamin B and fish oil fail to prevent cancer-study
February 13, 2012
'Hunger hormone' could help chemo patients: study
February 9, 2012
Most women with cancer want a role in decisions
February 8, 2012
Komen charity under microscope for funding, science
February 7, 2012
Ovarian cancer screening popular despite guidelines
February 3, 2012
Senators urge Komen to reconsider funding decision
February 1, 2012
Eating fish tied to lower risk of colon polyps
January 31, 2012
Kids seek tans, use less sunscreen as they Age
January 18, 2012
FDA approves BTG's drug for cancer toxicity
January 5, 2012
Argentina's Fernandez undergoes cancer surgery
December 20, 2011
Vitamin D has mixed effects on cancer, broken bones
December 13, 2011
Memory issues after cancer may not be due to chemo
View All Cancer News